What to watch with CYP2C19 and fatigue?

CYP2C19 is a key drug-metabolizing enzyme affecting medications like clopidogrel, proton pump inhibitors, and some antidepressants. Genetic variants can result in poor, intermediate, rapid, or ultrarapid metabolizer status. Fatigue is not a direct effect of CYP2C19 genotype, but it can arise indirectly: poor metabolizers may accumulate higher drug levels (e.g., omeprazole, escitalopram), increasing side effects including drowsiness or fatigue. Conversely, ultrarapid metabolizers may have reduced efficacy of clopidogrel, raising thrombotic risk, which can manifest as fatigue from cardiovascular strain. Evidence is based on pharmacogenomic studies, but specific large trials linking CYP2C19 to fatigue are lacking. Consumer DNA tests for CYP2C19 provide risk information, not a diagnosis. Fatigue has many causes (sleep, stress, nutrition, illness), so a single gene variant is rarely the explanation. If you take CYP2C19 substrates, discuss dose adjustments with your healthcare provider.